Patents by Inventor Kevin Gene Peters

Kevin Gene Peters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
    Publication number: 20140288134
    Abstract: Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.
    Type: Application
    Filed: June 10, 2014
    Publication date: September 25, 2014
    Applicant: AERPIO THERAPEUTICS INC.
    Inventors: Kevin Gene Peters, Robert Shalwitz
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
    Publication number: 20140249100
    Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
    Type: Application
    Filed: March 3, 2013
    Publication date: September 4, 2014
    Applicant: Aerpio Therapeutics Inc.
    Inventors: Robert Shalwitz Shalwitz, Kevin Gene Peters
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
    Publication number: 20140242026
    Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Inventors: Robert Shalwitz, Kevin Gene Peters
  • METHODS FOR TREATING VASCULAR LEAK SYNDROME
    Publication number: 20140066458
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Inventors: Robert Shalwitz, Kevin Gene Peters
  • ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES TEHREOF
    Publication number: 20140044707
    Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 13, 2014
    Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
  • METHODS FOR TREATING VASCULAR LEAK SYNDROME
    Publication number: 20130331386
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 12, 2013
    Inventors: Robert Shalwitz, Kevin Gene Peters
  • Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)
    Patent number: 8524235
    Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: September 3, 2013
    Assignee: Aeripo Therapeutics Inc.
    Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
  • COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
    Publication number: 20120129847
    Abstract: Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.
    Type: Application
    Filed: October 5, 2011
    Publication date: May 24, 2012
    Inventors: Kevin Gene Peters, Robert Shalwitz
  • ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
    Publication number: 20110274699
    Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.
    Type: Application
    Filed: May 25, 2011
    Publication date: November 10, 2011
    Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
  • Antibodies that bind human protein tyrosine phosphatase beta (HPTP?)
    Patent number: 7973142
    Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: July 5, 2011
    Assignee: Warner Chilcott Company
    Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
  • HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS
    Publication number: 20100056610
    Abstract: Disclosed herein is the use of HPTPbeta to screen agents useful in the treatment angiogenesis mediated disorders.
    Type: Application
    Filed: November 2, 2009
    Publication date: March 4, 2010
    Inventors: Kevin Gene Peters, Michael Glen Davis
  • Pharmaceutical compositions that modulate HPTPbeta activity
    Patent number: 7632862
    Abstract: HPTPbeta is useful as a target in screening agents effective for the treatment of angiogenesis mediated disorders.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: December 15, 2009
    Assignee: Procter & Gamble Company
    Inventors: Kevin Gene Peters, Michael Glen Davis
  • Methods and targets for identifying compounds for regulating angiogenesis
    Publication number: 20090178145
    Abstract: The present invention provides methods for identifying genes and proteins that may regulate angiogenesis. The genes identified may be used as markers for the disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents that are capable of regulating angiogenesis. The present invention also provides methods of identifying therapeutic compounds that may treat various disorders by regulating the expression and activity of genes and proteins identified.
    Type: Application
    Filed: May 10, 2006
    Publication date: July 9, 2009
    Applicant: The Procter & Gamble Company
    Inventors: Andrew Nicholas Carr, Kevin Gene Peters, Claus-Jens Walter Doersen, Xiaoyan Qu
  • Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
    Publication number: 20090022715
    Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.
    Type: Application
    Filed: April 5, 2007
    Publication date: January 22, 2009
    Applicant: The Procter & Gamble Company
    Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
  • HPTPbeta as a target in treatment of angiogenesis mediated disorders
    Patent number: 7226755
    Abstract: HPTPbeta is useful as a target in screening agents effective for the treatment of angiogenesis mediated disorders.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: June 5, 2007
    Assignee: The Procter & Gamble Company
    Inventors: Kevin Gene Peters, Michael Glen Davis
  • Phenethylamino sulfamic acids
    Publication number: 20040167183
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: August 4, 2003
    Publication date: August 26, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Sean Rees Klopfenstein, Matthew Brian Maier, David Robert Jones, Jeffrey Lyle Gray, Matthew Eugene Pokross, Kevin Gene Peters, Artem Gennady Evdokimov
  • Angiogenesis modulating proteins
    Publication number: 20030162706
    Abstract: Angiogenesis modulating proteins may be useful for treating angiogenesis mediated disorders. Further, these angiogenesis modulating proteins may be useful to screen agents that are, in turn, useful for treating angiogenesis mediated disorders.
    Type: Application
    Filed: December 10, 2002
    Publication date: August 28, 2003
    Applicant: The Procter & Gamble Company
    Inventors: Kevin Gene Peters, Larry Joseph Thompson, Feng Wang, Kenneth Donald Greis
  • Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
    Publication number: 20030158083
    Abstract: KDR associated phosphatase (KAPh) is useful as a target to screen for agents useful for the treatment of angiogenesis mediated disorders.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 21, 2003
    Applicant: The Procter & Gamble Company
    Inventor: Kevin Gene Peters